肝纤维化与肝硬化患者肝内CXCL13和CXCL16的表达变化

Hepatic expressions of CXCL13 and CXCL16 in patients with hepatic fibrosis and cirrhosis and in normal controls

目的观察肝纤维化与肝硬化患者肝组织中趋化因子CXCL13和CXCL16的表达变化。方法用ELISA方法分别检测9例正常人和10例肝纤维化、11例肝硬化患者肝组织中的CXCL13和CXCL16含量。结果正常对照组、肝纤维化组、肝硬化组的CXCL13浓度分别为(2.34±2.05)ng/g、(6.04±2.97)ng/g和(12.10±10.38)ng/g;肝硬化组的浓度显著高于正常对照组和肝纤维化组,正常对照组与肝纤维化组的CXCL13浓度差异无统计学意义。正常对照组、肝纤维化组、肝硬化组的CXCL16浓度分别为(1.32±0.91)ng/g、(3.34±1.81)ng/g和(3.49±1.90)ng/g;肝硬化组和肝纤维化组浓度均显著高于正常对照组浓度,肝硬化组和肝纤维化组的CXCL16浓度差异无统计学意义。结论肝脏发生纤维化损伤时,肝脏表达CXCL13和CXCL16的数量都显著增多,但两者的变化规律不同。肝内CXCL13水平在肝纤维化阶段开始升高,至肝硬化阶段升高到显著水平。肝内CXCL16水平在肝纤维化阶段就已经升高到显著水平,至肝硬化阶段仍维持在高水平状态。

Objective To investigate the expression of chemotactic factors （CXCL13 and CXCL16） in the liver of patients with hepatic fibrosis and cirrhosis and in normal controls. Methods Hepatic tissues were obtained in surgery from 9 normal persons,10 patients with hepatic fibrosis,and 11 patients with cirrhosis. Expression of CXCL13 and CXCL16 in hepatic tissues was quantified by ELISA. Results The concentrations of CXCL13 were 2.34±2.05,6.04±2.97 and 12.10±10.38 ng/g in normal,hepatic fibrosis and hepatic cirrhosis group,respectively. CXCL13 in sclerotic liver was higher than that in normal controls and fibrotic liver,but there was no significant difference. The concentrations of CXCL16 were 1.32±0.91,3.34±1.81 and 3.49±1.90 ng/g in normal,hepatic fibrosis and hepatic cirrhosis group. CXCL16 in fibrotic liver and sclerotic liver were higher than that in normal liver,but there was still no significant difference. Conclusion With the aggravation of hepatic fibrous degeneration,hepatic levels of CXCL13 and CXCL16 increase,but follow a different way. CXCL13 begins to rise in the stage of liver fibrosis and has a significant increase in cirrhosis stage. CXCL16 increases to significant level in the stage of liver fibrosis,and remains in a high state in liver cirrhosis stage.